Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterion

Digestion

Volumn 78, Issue 2-3, 2008, Pages 120-122

  Tillmann, Hans L ^a,b   Thompson, Alexander J V ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; OPIATE; PEGINTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG RESISTANCE; DRUG TOXICITY; EDITORIAL; FIBROSIS; HEALTH SERVICE; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENCE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL PSYCHOLOGY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT REFUSAL; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG USERS; HEPATITIS C; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 56349123431     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173732     Document Type: Editorial

References (18)

1. Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Goergen B, Detmer J, McMorrow M, Stoll M, Schmidt RE, Manns MP: Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001;345:715-724.
2. Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, Isler M, Broers B, Kölliker C, Schönbucher P, Frei M, Huber M: Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 2008;78:123-130.
3. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67:117-123.
4. Van Thiel DH, Anantharaju A, Creech S: Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003;98:2281-2288.
5. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G: A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124.
6. Tillmann HL: Hepatitis C virus infection. N Engl J Med 2001;345:1426.
7. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ: Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938-945.
8. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
9. Eshaghian S, Horwich TB, Fonarow GC: An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91.
10. Gluud C, Brok J, Gong Y, Koretz RL: Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007;46:734-742.
11. Tillmann HL: Hepatitis C virus infection. N Engl J Med 2001;345:1426.
12. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL, The Interventional Therapy Group: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999;30:550-555.
13. 2b in combination with ribavirin on health-related quality of life and work productivity. J Hepatol 2001;34:140-147.
14. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
15. Younossi Z, Kallman J, Kincaid J: The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-816.
16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
18. Aus dem Siepen M, Oniangue-Ndza C, Wiese M, Ross S, Roggendorf M, Viazov S: Interferon-α and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon. Virus Res 2007;125:109-113.